Arcagy/ Gineco Group
Clinical trials sponsored by Arcagy/ Gineco Group, explained in plain language.
-
Hope for rare cancer: new combo aims to outperform chemo
Disease control Recruiting nowThis study tests whether combining two drugs (dostarlimab and niraparib) works better than either drug alone or standard chemotherapy for women with a rare, aggressive uterine or ovarian cancer called carcinosarcoma. About 138 women whose cancer has spread or returned after at le…
Phase: PHASE2, PHASE3 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
Promising combo may boost survival in rare ovarian cancer
Disease control Recruiting nowThis study tests whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy can improve outcomes for people with a rare and aggressive ovarian cancer called small cell ovarian carcinoma of hypercalcemic type. About 27 participants aged 12 and older will receive…
Phase: PHASE2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New hope for ovarian cancer: study tests best way to keep cancer away after initial treatment
Disease control Recruiting nowThis study is for women with advanced ovarian cancer who have had complete surgery and chemotherapy. It compares two maintenance therapies: niraparib alone versus niraparib plus bevacizumab. The goal is to see which combination better prevents the cancer from coming back. About 3…
Phase: PHASE2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC